Checked
AIM ImmunoTech Inc.
NYSE: AIM · Biological Products, (No Diagnostic Substances) · Ocala, FL
- Revenue
- $88K
- -48.2% vs. prior year
- Net income
- -$13.96M
- -15861.4% net margin
- Total assets
- $5.78M
- Diluted EPS
- -$8.62
Company details
As reported to the SEC
- SEC CIK
- 946644
- Stock
- NYSE: AIM
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- Headquarters
- 2117 SW Highway 484, Ocala, FL 32801
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Non-accelerated filer, Smaller reporting company
- Phone
- (352) 448-7797
- Employer ID (EIN)
- 52-0845822
- Last annual report
- 03/27/2026
- Last quarterly report
- 08/07/2026
Formerly: HEMISPHERX BIOPHARMA INC (until 08/26/2019)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $88K | $170K | $202K | $141K | $135K |
| Operating income | -$11.66M | -$19.77M | -$31.92M | -$19.92M | -$18.84M |
| Net income | -$13.96M | -$17.32M | -$28.96M | -$19.45M | -$19.13M |
| Diluted earnings per share | -$8.62 | -$30.92 | -$0.60 | -$0.40 | -$0.40 |
| Research and development | $3.92M | $6.2M | $10.94M | $6.99M | $7.67M |
| Total assets | $5.78M | $8.61M | $19.38M | $40.49M | $57.7M |
| Total liabilities | $15.56M | $9.93M | $9.15M | $2.02M | Not reported |
| Shareholders' equity | -$9.78M | -$1.32M | $10.23M | $38.47M | $56.88M |
| Cash and cash equivalents | $2.98M | $1.7M | $5.44M | $27.05M | $32.09M |
| Long-term debt | $927K | $2.81M | Not reported | Not reported | Not reported |
| Cash from operations | -$10.96M | -$14.89M | -$21.27M | -$16.11M | -$13.96M |
| Capital expenditures | Not reported | $18K | Not reported | $86K | $41K |
Recent filings
153 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
11 insider ownership reports (Forms 3, 4, 5 and 144) were filed about AIM ImmunoTech Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other biological products, (no diagnostic substances)
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Amgen IncAMGN | Thousand Oaks, CA | $36.75B | $7.71B |
| Gilead Sciences, Inc.GILD | Foster City, CA | $29.44B | $8.51B |
| Biogen Inc.BIIB | Cambridge, MA | $9.89B | $1.29B |
| Neurocrine Biosciences IncNBIX | San Diego, CA | $2.86B | $478.6M |
| Exelixis, Inc.EXEL | Alameda, CA | $2.32B | $782.6M |
| Qiagen N.V.QGEN | Pl Venlo, Netherlands | $2.09B | $424.9M |
| Moderna, Inc.MRNA | Cambridge, MA | $1.94B | -$2.82B |
| Halozyme Therapeutics, Inc.HALO | San Diego, CA | $1.4B | $316.9M |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is AIM ImmunoTech Inc.'s CIK number?
- AIM ImmunoTech Inc.'s SEC Central Index Key (CIK) is 946644.
- What is AIM ImmunoTech Inc.'s stock ticker?
- AIM ImmunoTech Inc. trades as NYSE: AIM.
- What was AIM ImmunoTech Inc.'s revenue?
- AIM ImmunoTech Inc. reported revenue of $88K for the fiscal year ended Dec 31, 2025, -48.2% from the year before.
- When does AIM ImmunoTech Inc.'s fiscal year end?
- AIM ImmunoTech Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is AIM ImmunoTech Inc. headquartered?
- AIM ImmunoTech Inc.'s principal executive office on file with the SEC is in Ocala, FL.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026